Certain ADC therapies for HER2-enriched breast tumors have shown promising efficacy against HER2-low tumors including trastuzumab-duocarmazin (SYD 985), disitamab-vedotin (RC48) (Shi et al., 2022) and durvalumab and T-Dxd (Popović et al., 2023). The gene discussed is ERBB2; the disease is breast neoplasm.